Skip to main content
Fig. 2 | Cell Communication and Signaling

Fig. 2

From: PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis

Fig. 2

PRMT5 regulates the proliferation and tumorigenicity of pancreatic cancer cells a. PRMT5 expression in pancreatic cancer cell lines. b. Quantitative real-time results confirmed the silencing efficiency of shRNAs targeting PRMT5 in MIA PaCa-2 and SW1990 cells. c. Immunoblotting with an anti-PRMT5 antibody further confirmed that PRMT5 was efficiently silenced in MIA PaCa-2 and SW1990 cells. d. Silencing of PRMT5 decreased the viability of MIA PaCa-2 and SW1990 cells (n = 3, p < 0.05 and p < 0.01 for the shPRMT5A and shPRMT5B groups, respectively). e-f. Silencing of PRMT5 inhibited the colony formation capacity of MIA PaCa-2 and SW1990 cells (n = 3, p < 0.01). g-h. The subcutaneous xenograft mouse model showed that knockdown of PRMT5 decreased the tumor formation capacity of SW1990 cells (n = 4, p < 0.001). i. Representative images of immunohistochemical staining for Ki-67 and PRMT5

Back to article page